Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $171M (up 0.4% year over year) with net income of $6M.
Q1 2026 key financials · XBRL
- Revenue
- $171M
- +0.4% YoY
- Net income
- $6M
- −74.6% YoY
- Operating margin
- 8.0%
- Gross margin
- 41.1%
- EPS (diluted)
- $0.14
- −72.5% YoY
Source: XBRL data from the Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 10-Q on SEC EDGAR. USD.
Amphastar Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: South El Monte FDA inspection classified “Official Action Indicated” in April 2026 after December 2025 observations
- cGMP compliance risk: Corrective actions may fail, potentially causing production suspension, recalls, penalties, or delayed approvals
- Share-price risk: Lenders could force sales of pledged shares securing $57.0 million of credit lines
- Financial concentration risk: UBS may unilaterally call $15.0 million of credit lines for any reason
- Market risk: Forced lender sales could further depress Amphastar’s common-stock price
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amphastar Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.